Nektar Therapeutics Sees 38% Stock Surge Amid Key Updates

Introduction

Nektar Therapeutics (NASDAQ: NKTR) is a research-stage biopharmaceutical company focused on immune-modulating therapies for autoimmune disorders, chronic inflammatory conditions, and cancer. On June 25, 2025, NKTR shares closed at $33.75, reflecting a 38.04 percent increase on a trading volume of 7,580,451 shares on the NASDAQ exchange.

Corporate Structure

Founded in 1990, Nektar employs between 501 and 1,000 people across its headquarters in San Francisco, California, a former manufacturing site in Huntsville, Alabama, and a research and development facility in Hyderabad, India. The company utilizes a proprietary polymer conjugate chemistry platform and maintains collaborations with various pharmaceutical and biotechnology companies.

Recent Developments and News

In February 2025, the U.S. Food and Drug Administration granted Fast Track designation to rezpegaldesleukin (REZPEG) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 and older. Additionally, that month, Nektar announced the completion of target enrollment in the REZOLVE-AA Phase 2b study, a global trial of REZPEG involving 84 patients with severe-to-very-severe alopecia areata.
On April 12, 2025, the European Hematological Association selected a collaborative abstract highlighting the combination of NKTR-255 with lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma.
On May 8, 2025, Nektar reported first-quarter financial results, which included revenue of $10.5 million compared to $21.6 million in Q1 2024, and a net loss of $50.9 million (or $0.24 per share) versus a $36.8 million loss a year earlier. As of March 31, 2025, the company reported cash and marketable securities totaling $220.7 million, expected to support operations into Q4 2026.
On June 24, 2025, Nektar plans to announce top-line data from the 16-week induction period of the REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis.

Financial and Strategic Aspects

Nektar's operating expenses for Q1 2025 totaled $55.0 million, down from $57.1 million in Q1 2024, largely due to the elimination of manufacturing costs following the sale of its Huntsville facility in December 2024. Research and development expenses increased to $30.5 million from $27.4 million, primarily due to increased investment in REZPEG, while general and administrative costs rose to $24.3 million because of higher legal expenses. Excluding a $4.5 million non-cash loss from equity method investments, the adjusted net loss was $46.4 million, or $0.22 per share.
Strategically, Nektar is advancing several pipeline candidates: rezpegaldesleukin targeting dermatological and autoimmune indications; NKTR-0165, an anti-TNFR2 antibody for conditions such as multiple sclerosis; and a bispecific TNFR2-targeting antibody entering preclinical studies. Collaborations with industry partners are integral to its clinical programs and commercialization strategy.

Market Position and Industry Context

As a development-stage company, Nektar operates within the immune modulation sector, where regulatory approval and clinical validation are critical for establishing market value. The company's proprietary polymer conjugation technology provides differentiation; however, late-stage clinical trial outcomes and regulatory decisions will influence its market positioning. Nektar's focus on autoimmune and oncology-related therapies places it among a diverse range of competitors, from specialized biotechnology firms to larger pharmaceutical companies, all seeking advancements in immunotherapy.

tl;dr

NKTR stock rose 38.04 percent to $33.75 on June 25, 2025. Q1 2025 results indicated revenue of $10.5 million, a net loss of $50.9 million, and a projected cash runway into Q4 2026. Key upcoming milestones include Fast Track status for REZPEG in atopic dermatitis, completion of enrollment in alopecia areata, and the anticipated announcement of top-line data from the REZOLVE-AD Phase 2b study on June 24, 2025, as well as a planned IND submission for NKTR-0165 by year-end.